Bulent Ozpolat Selected Research

Elongation Factor 2 Kinase

3/2022	Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: homology modeling, molecular docking, and molecular dynamics simulation.
11/2021	Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
1/2021	Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
1/2020	Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors.
1/2020	Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
10/2018	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
10/2018	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
8/2017	Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
2/2017	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
3/2016	FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bulent Ozpolat Research Topics

Disease

78	Neoplasms (Cancer) 07/2022 - 05/2003
17	Breast Neoplasms (Breast Cancer) 11/2021 - 07/2008
14	Triple Negative Breast Neoplasms 03/2022 - 07/2015
13	Neoplasm Metastasis (Metastasis) 07/2022 - 05/2010
13	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 04/2014
12	Carcinogenesis 01/2022 - 05/2010
11	Pancreatic Neoplasms (Pancreatic Cancer) 03/2020 - 03/2007
8	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 12/2012
7	Acute Promyelocytic Leukemia 01/2019 - 05/2002
4	Adenocarcinoma 01/2022 - 11/2014
4	Hypoxia (Hypoxemia) 01/2020 - 04/2010
3	Leiomyoma (Uterine Fibroids) 08/2022 - 11/2016
3	Leukemia 07/2013 - 05/2002
2	Disease Progression 05/2022 - 03/2016
2	Lung Neoplasms (Lung Cancer) 01/2020 - 10/2018
2	Starvation 01/2019 - 03/2018
2	Glioma (Gliomas) 06/2015 - 03/2014
2	Liver Neoplasms (Liver Cancer) 01/2014 - 01/2014
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2012 - 05/2004
1	Human Influenza (Influenza) 07/2022

Drug/Important Bio-Agent (IBA)

22	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2007
20	Proteins (Proteins, Gene)FDA Link 03/2022 - 01/2007
15	MicroRNAs (MicroRNA)IBA 03/2022 - 01/2016
13	Phosphotransferases (Kinase)IBA 03/2022 - 01/2014
11	Elongation Factor 2 KinaseIBA 03/2022 - 01/2012
8	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 05/2002
7	Pharmaceutical PreparationsIBA 03/2022 - 10/2005
7	Biological ProductsIBA 05/2021 - 11/2011
7	IntegrinsIBA 05/2021 - 01/2014
7	Messenger RNA (mRNA)IBA 01/2020 - 03/2007
6	Protein Glutamine gamma Glutamyltransferase 2IBA 01/2014 - 01/2007
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
5	Beclin-1IBA 01/2021 - 09/2007
4	Lipid NanoparticlesIBA 07/2022 - 01/2021
4	Transcription Factors (Transcription Factor)IBA 01/2021 - 06/2015
4	AndrogensIBA 01/2019 - 12/2012
4	Cyclin D1IBA 10/2018 - 05/2010
4	Matrix Metalloproteinases (MMPs)IBA 05/2015 - 01/2014
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 04/2014
3	Docetaxel (Taxotere)FDA Link 01/2021 - 11/2011
3	Serotonin (5 Hydroxytryptamine)IBA 11/2016 - 01/2014
3	Serotonin ReceptorsIBA 11/2016 - 01/2014
3	Arsenic Trioxide (Trisenox)FDA Link 01/2012 - 07/2008
2	Peptides (Polypeptides)IBA 07/2022 - 04/2014
2	NucleoproteinsIBA 07/2022 - 09/2004
2	Protein Kinases (Protein Kinase)IBA 03/2022 - 03/2007
2	Untranslated RNA (Noncoding RNA)IBA 01/2022 - 01/2021
2	Chalcone (Benzalacetophenone)IBA 06/2021 - 04/2021
2	LipidsIBA 04/2021 - 02/2014
2	NF-kappa B (NF-kB)IBA 01/2021 - 10/2018
2	thymoquinoneIBA 01/2021 - 10/2018
2	Estrogens (Estrogen)FDA Link 01/2021 - 06/2013
2	Activating Transcription Factor 4IBA 01/2021 - 01/2019
2	Sucrose (Saccharose)IBA 03/2020 - 04/2019
2	Hyaluronic Acid (Hyaluronan)IBA 03/2020 - 04/2019
2	NanogelsIBA 03/2020 - 04/2019
2	GoldIBA 08/2017 - 01/2016
2	Estrogen ReceptorsIBA 02/2017 - 09/2013
2	Antineoplastic Agents (Antineoplastics)IBA 07/2015 - 04/2010
2	CytokinesIBA 05/2015 - 02/2012
2	rottlerinIBA 01/2014 - 03/2007
2	Tamoxifen FDA LinkGeneric 06/2013 - 04/2010
2	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2013 - 01/2012
2	Retinoic Acid 4-Hydroxylase (CYP26B1)IBA 10/2005 - 05/2002
2	RetinoidsIBA 05/2004 - 05/2003
1	Simvastatin (Zocor)FDA LinkGeneric 08/2022
1	Liposomes (Liposome)IBA 08/2022
1	AntigensIBA 07/2022
1	Hemagglutinins (Hemagglutinin)IBA 07/2022
1	Epidermal Growth Factor (EGF)IBA 07/2022
1	AntagomirsIBA 01/2022
1	coumarinIBA 11/2021
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2021
1	Eukaryotic Initiation Factor-4EIBA 02/2021
1	Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)IBA 02/2021
1	CarcinogensIBA 02/2021
1	abirateroneIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Abiraterone AcetateIBA 01/2021
1	Progesterone FDA LinkGeneric 01/2021
1	ChemokinesIBA 01/2021
1	Androgen Antagonists (Antiandrogens)IBA 01/2021
1	src-Family KinasesIBA 01/2021
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2021
1	Mercaptoethanol (2 Mercaptoethanol)IBA 01/2021
1	2-MethoxyestradiolIBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	Caspase 3 (Caspase-3)IBA 01/2021
1	rhodamine 6GIBA 03/2020
1	Biocompatible Materials (Biomaterials)IBA 03/2020

Therapy/Procedure

34	Therapeutics 07/2022 - 07/2008
10	Drug Therapy (Chemotherapy) 01/2021 - 07/2008
3	Immunotherapy 07/2022 - 01/2017
3	Precision Medicine 01/2022 - 01/2016
2	Chemoprevention 01/2019 - 03/2018
2	Intravenous Administration 01/2018 - 02/2014
2	Radiotherapy 01/2015 - 04/2010
1	RNAi Therapeutics 01/2022
1	Aftercare (After-Treatment) 01/2021